Recent advances in therapy of chronic lymphocytic leukaemia (Q38862525)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	Recent advances in therapy of chronic lymphocytic leukaemia	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

1 reference

Europe PubMed Central

Recent advances in therapy of chronic lymphocytic leukaemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

0 references

1 reference

based on heuristic

inferred from title

David Routledge

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27291144%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

author name string

Adrian J C Bloor

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27291144%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

language of work or name

0 references

publication date

13 June 2016

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27291144%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

174

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27291144%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27291144%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

351-367

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27291144%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia?

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Choosing first-line therapy for chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Targeted therapies for CLL: Practical issues with the changing treatment paradigm

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

How will B-cell-receptor-targeted therapies change future CLL therapy?

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

New insights into pre-BCR and BCR signalling with relevance to B cell malignancies

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Chemoimmunotherapy with fludarabine, cytoxan and rituximab regimen: to use, not to use, or give it as "FCR-LITE"?

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

The B-cell receptor signaling pathway as a therapeutic target in CLL.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14184

21 January 2018

Identifiers

10.1111/BJH.14184

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27291144%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27291144%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38862525&oldid=1791391872"